Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

December 29, 2014
Irene Ghobrial

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Antibodies offer limited toxicity and can be used in combination together for maximum result.

The anti-CXCR4 antibody ulocuplumab has exciting potential, says Ghobrial. The antibody has shown promising results in combination with lenalidomide (Revlimid) plus dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Related Content:

Onclive TV | Multiple Myeloma

x